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Abstract
Background: Ukraine’s injecting drug use-driven HIV epidemic is among the most severe in Europe with high
burden of HCV co-infection. HIV/HCV co-infected individuals are at elevated risk of HCV-related morbidity, but little
is known about burden of liver disease and associated factors in the HIV-positive population in Ukraine, particularly
among women.
Methods: Characteristics of 2050 HIV-positive women enrolled into the Ukrainian Study of HIV-infected
Childbearing Women were described by HCV serostatus. Aspartate transaminase (AST) to platelet ratio (APRI) and
FIB-4 scores were calculated and exact logistic regression models fitted to investigate factors associated with
significant fibrosis (APRI >1.5) among 762 women with an APRI score available.
Results: Of 2050 HIV-positive women (median age 27.7 years, IQR 24.6-31.3), 33% were HCV co-infected (79% of
those with a history of injecting drug use vs 23% without) and 17% HBsAg positive. A quarter were on antiretroviral
therapy at postnatal cohort enrolment. 1% of the HIV/HCV co-infected group had ever received treatment for HCV.
Overall, 24% had an alanine aminotransferase level >41 U/L and 34% an elevated AST (53% and 61% among HIV/
HCV co-infected). Prevalence of significant fibrosis was 4.5%; 2.5% among 445 HIV mono-infected and 12.3% among
171 HIV/HCV co-infected women. 1.2% had a FIB-4 score >3.25 indicating advanced fibrosis. HCV RNA testing in a
sub-group of 56 HIV/HCV co-infected women indicated a likely spontaneous clearance rate of 18% and predominance
of HCV genotype 1, with one-third having genotype 3 infection. Factors associated with significant fibrosis were HCV
co-infection (AOR 2.53 95%CI 1.03-6.23), history of injecting drug use (AOR 3.51 95%CI 1.39-8.89), WHO stage 3-4 HIV
disease (AOR 3.47 95%CI 1.51-7.99 vs stage 1-2 HIV disease) and not being on combination antiretroviral therapy (AOR
3.08 95%CI 1.23-7.74), adjusted additionally for HBV co-infection, smoking and age.
Conclusions: Most HIV/HCV co-infected women had elevated liver enzymes and 12% had significant fibrosis according
to APRI. Risk factors for liver fibrosis in this young HIV-positive population include poorly controlled HIV and high
burden of HCV. Results highlight the importance of addressing modifiable risk factors and rolling out HCV treatment to
improve the health outcomes of this group.
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Background
An estimated 184 million people or 2.8% worldwide are
seropositive for hepatitis C virus (HCV) [1] with infec-
tions in Europe concentrated within non-EU/ EFTA
countries [2]. Prevalence of anti-HCV and hepatitis B
surface antigen (HBsAg) are both substantially higher
among people living with HIV but vary between popula-
tions, reflecting differing modes of HIV acquisition [3].
In Eastern Europe and Central Asia, where the HIV epi-
demic has historically been driven by injecting drug use
(IDU), around 40% of people living with HIV are HCV
co-infected, accounting for over a quarter of HIV/HCV
co-infections worldwide [3]. As in Western Europe,
genotype (GT) 1 predominates [4].
Liver disease is a leading cause of death among HIV-
positive populations, with severe immunosuppression
associated with liver-related death independently of viral
hepatitis co-infection [5]. HCV-related liver disease pro-
gression is accelerated in the presence of HIV co-
infection [6] and the large reductions in mortality risk
seen with combination antiretroviral therapy (cART) in
HIV mono-infected individuals are not matched in HIV/
HCV co-infected patients [7]. Although studies of HCV
mono-infection have indicated slower liver disease pro-
gression in pre-menopausal women than in men, due to
oestrogen-mediated and other effects [8], whether this is
true for women co-infected with HIV remains unclear
[9]. Other factors associated with faster liver fibrosis
progression in HIV/HCV co-infection include older age
at diagnosis, longer duration of infection, lower CD4
count and alcohol use [10]. HIV/HCV co-infected preg-
nant women have a vertical HCV transmission risk of
around 10-11%, almost twice that of HCV mono-
infected women [11].
Despite historically worse outcomes with interferon-
based HCV treatment, HIV/HCV co-infected patients
treated with directly acting antivirals (DAA) can now ex-
pect outcomes on a par with HCV mono-infected indi-
viduals [12–14]. However, the high cost of DAAs
currently limits access, particularly in low and middle in-
come countries [15].
Quantification of liver fibrosis and associated risk fac-
tors among people living with HIV is important in un-
derstanding potential future liver disease burden, to
inform policies for minimising the impact of modifiable
risk factors on disease progression and for identifying
groups most urgently requiring HCV treatment. The
FIB-4 index and the aspartate transaminase (AST) to
platelet ratio (APRI) are algorithms allowing calculation
of a score indicating likelihood of significant or advanced
fibrosis from routinely available blood tests [16, 17];
these surrogate markers have been validated in HIV/
HCV co-infected adults and are particularly useful for
assessing liver fibrosis in resource-constrained settings
such as Ukraine, where other non-invasive measures
such as hepatic transient elastography or direct serologic
markers are unavailable.
The overall aim of this study was to investigate
markers of liver injury (i.e. elevated transaminases) and
fibrosis in postnatal women living with HIV with and
without HCV-co-infection in Ukraine. Specific objectives
were to assess the prevalence of and factors associated
with significant liver fibrosis, as measured by surrogate
biomarkers, and to describe HCV viral characteristics
(GT and viral load) for a sub-set of HIV/HCV co-
infected women.
Methods
Study population
The Ukrainian Study of HIV-infected Childbearing
Women, nested within the Ukraine European Collabora-
tive Study (ECS), enrolled HIV-positive childbearing
women with informed consent at five regional HIV/
AIDS centres in Ukraine between 2007 and 2012,
around 3-6 months after delivery [18]. Clinical data re-
ported by the clinician included HIV co-infections, liver
function test (LFT) and haematological test results, HIV
disease status and ART. Women self-reported socio-
demographic characteristics and health behaviours (in-
cluding drug use and smoking). Updated clinical data
were collected at routine follow-up visits. Unique study
numbers were used to match records from this postnatal
cohort with those in the Ukraine ECS, to obtain data on
antenatal ART use and timing of HIV diagnosis [19].
As HCV GT and HCV RNA tests are not part of rou-
tine clinical care in Ukraine, information on these fac-
tors were sought as part of a sub-study from March to
July 2013 in 56 HIV-positive HCV-seropositive women
who had never received HCV treatment and consented
for these additional tests. The 56 women were recruited
at one regional centre (in Kiev), and all HCV GT and
RNA tests were conducted at the same lab using real
time PCR amplificator Rotor-Gene ("Corbett Research",
Australia) and AmpliSense HCV-genotype-FL test kits,
Russia, sensitivity 5x1000 IU/ml (1.35x10000 copies/ml).
Analyses were conducted among the 2050 women en-
rolled in the postnatal cohort with HCV serostatus avail-
able, and the sample of 56 women with additional HCV
test results. The presence of liver fibrosis was assessed
based on APRI and FIB-4.
The ECS has ethics approval from the Great Ormond
Street Hospital for Children NHS Trust/Institute of
Child Health Research Ethics Committee (reference
96 EB02). Ethics approval for additional HCV RNA and
GT testing conducted with consent as part of this study
was obtained from the UCL Research Ethics Committee
(3061/002) and from the Ethics Committee of the
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Shupyk National Medical Academy of Postgraduate Edu-
cation in Kiev.
Definitions
APRI scores were calculated as (AST/upper limit of
normal [ULN]) /platelet count x 100, with values of
<0.5 indicating the absence and values of >1.5 indicat-
ing the presence of significant liver fibrosis (equiva-
lent to METAVIR ≥ F2) [16]. FIB-4 scores were
calculated using age and AST, alanine aminotransfer-
ase (ALT) and platelet levels. FIB-4 scores of <1.45
indicate absence of fibrosis and those >3.25 indicate
advanced fibrosis (METAVIR ≥ F3) [17]. Scores for
each measure which fell between the two cut-offs
were defined as indeterminate.
Hepatitis B co-infected women were defined as those
positive for HBsAg and HCV co-infected women as
those with HCV antibodies. The ULN was taken as 38
U/L for AST and 41 U/L for ALT [20]; an ULN of 19
was also used to describe ALT measures, as this lower
ULN may be more sensitive in identifying individuals
with liver injury / hepatitis C viremia [21]. LFT eleva-
tions were categorised as mild, moderate or severe /po-
tentially life threatening using the Division of AIDS
(DAIDS) grading criteria [22]. IDU was defined by self-
report, clinical assessment or neonatal abstinence syn-
drome in the woman’s infant (apparent in 60-80% of in-
fants exposed to opiates in-utero [23]). Smoking status
was determined at postnatal cohort enrolment.
Selection of LFTs for analysis and calculation of APRI and
FIB-4
The first eligible liver function and platelet results re-
ported after delivery were used to calculate one APRI
and one FIB-4 score for each woman; eligible test results
were based on ≥1 blood samples taken within seven
days. Results taken during pregnancy were excluded.
Women with no LFTs reported up to their last date of
follow-up or up to three years after delivery (whichever
was earlier) were excluded, as were any women whose
first results reported were during a subsequent preg-
nancy, due to the normal fluctuations in ALT, AST and
platelet levels which occur during pregnancy [20] poten-
tially affecting the validity of APRI and FIB-4. Women
missing hepatitis B status (n = 95) were excluded from
analyses of LFTs, APRI and FIB-4 scores.
Statistical analysis
Chi-squared or Fisher’s exact tests were used for univari-
able comparisons of categorical variables and the
Wilcoxon-Mann-Whitney rank sum test for comparing
location in continuous variables. Exact logistic regression
models were fitted to assess factors associated with sig-
nificant fibrosis (i.e. APRI score >1.5), but not for
advanced fibrosis (i.e. FIB-4 > 3.25), as the low preva-
lence of this more severe outcome precluded adjusted
analyses. Variables associated with the outcome (p < 0.1)
in univariable analyses were included in the multivari-
able model, in addition to hepatitis B co-infection status
and postnatal ART use a priori. An interaction term was
fitted to test the joint effect of IDU and HCV co-
infection in a separate model. A sensitivity analysis was
also conducted excluding women with a diagnosis of tu-
berculosis due to possible hepatic involvement. Statis-
tical analysis was performed using STATA version 13
(Stata Corp LP, College Station USA).
Results
A third (n = 677) of the 2050 HIV-positive women were
HCV seropositive. Table 1 shows socio-demographic and
clinical characteristics by HCV serostatus. Median age
was 27.7 years (IQR 24.6-31.3). One-fifth of women had
an IDU history, of whom 79% (314/398) had HCV anti-
bodies, compared with 23% (333/1461) of those without
IDU history. HCV-seropositive women were older than
HCV-seronegative women (Table 1). HIV diagnosis oc-
curred a median 16.5 months (IQR 8.6-35.9) prior to en-
rolment, for two-thirds during their most recent
pregnancy. Almost all (96%, 1810/1879) women had re-
ceived antenatal ART, with 28% (575/2029) on ART at
postnatal cohort enrolment, at a median of 5.0 months
(IQR 1.1-10.0) postpartum. Among the 37% (758/2050)
of women with a CD4 count ≤350 cells/mm3 or WHO
stage 3 or 4 disease (i.e. indications for treatment ac-
cording to WHO guidelines at the time), postnatal treat-
ment coverage was 61% (459/758), with no difference by
HCV serostatus (χ2 = 0.08 p = 0.77). Among 512 with
data available on type of ART received postnatally, 75%
(n = 385) were on a ritonavir-boosted lopinavir-based
regimen (of whom 249 received lopinavir in combination
with zidovudine and lamivudine) and 17% (n = 86) were
on a nevirapine-based regimen. Of 329 HBV infected
women, 115 were on ART postnatally and 107 had infor-
mation available on type of ART; among these 107, 35
(33%) were on a tenofovir-containing regimen. Of 6%
(109/1783) who conceived their most recent pregnancy
while on ART, almost all (n = 103) remained on ART
postnatally. Only 1% (7/558) with data available had re-
ceived HCV treatment by enrolment.
HCV genotype and viral load
Among the sub-group of 56 HCV-seropositive women
tested for HCV RNA and GT (median 32.0 years), IDU
history was reported in 39% (21/54); none were positive
for HBsAg. Ten (18%) were non-viremic for HCV.
Among 46 women with detectable HCV RNA (i.e. >200
copies/ml) median viral load was log10 5.58 copies/ml
(IQR 5.18-6.08): 9 (20%) had GT1a, 20 (43%) GT1b, 1
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Table 1 Socio-demographic and clinical characteristics by HCV serostatus at postnatal cohort enrolment
Total (n = 2050) HCV antibody negative (n = 1383) HCV antibody positive (n = 667) p value
n (%) or median [IQR]
Age (n = 2047) (years) 27.7
[24.6, 31.3]
27.1
[24.1, 30.6]
29.1
[26.2, 32.6]
p < 0.01
Age at leaving full-time education (n = 1429)a
≤ 16 years 331 (23) 159 (17) 172 (34) p < 0.01
17–18 years 378 (26) 249 (27) 129 (25)
≥ 19 years 720 (50) 515 (56) 205 (41)
History of IDU (n = 1859)
No 1461 (79) 1128 (93) 333 (51) p < 0.01
Yes 398 (21) 84 (7) 314 (49)
Ever had an IDU sex partner (n = 1765)
No 1416 (80) 1025 (87) 391 (66) p < 0.01
Yes 349 (20) 149 (13) 200 (34)
History of imprisonment (n = 1930)
No 1862 (96) 1274 (99) 588 (92) p < 0.01
Yes 68 (4) 16 (1) 52 (8)
Timing of HIV diagnosis (n = 1873)a
Before most recent pregnancy 701 (37) 398 (32) 303 (48) p < 0.01
During most recent pregnancy 1172 (63) 842 (68) 330 (52)
CD4 count (n = 1918), (cells/mm3, median [IQR]) 452 [324, 604] 460 [335, 609] 426 [299, 591] p < 0.01
CD4 count (n = 1918)
≤ 350 cells/mm3 566 (30) 356 (28) 210 (33) p = 0.03
351-500 cells/mm3 582 (30) 395 (31) 187 (30)
> 500 cells/mm3 770 (40) 538 (42) 232 (37)
WHO stage (n = 2041)
Stage 1 1424 (70) 1065 (77) 359 (54) p < 0.01
Stage 2 269 (13) 145 (11) 124 (19)
Stage 3 267 (13) 124 (9) 143 (21)
Stage 4 81 (4) 41 (3) 40 (6)
On ART (n = 2029)
No 1454 (72) 1012 (74) 442 (67) p < 0.01
Yes 575 (28) 357 (26) 218 (33)
Hepatitis B co-infection (n = 1955)
No 1626 (83) 1170 (86) 456 (76) p < 0.01
Yes 329 (17) 184 (14) 145 (24)
Smoking history (n = 2021)
Never smoked 578 (29) 460 (34) 118 (18) p < 0.01
Past smoker 484 (24) 364 (27) 120 (18)
Current smoker, <15 cigarettes /day 417 (21) 304 (22) 113 (17)
Current heavy smoker, ≥15 cigarettes /day 440 (22) 176 (13) 264 (40)
Current smoker, cigarettes/day not reported 102 (5) 57 (4) 45 (7)
aAvailable for women with matched pregnancy data from the ECS only
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uncategorised GT1 and 16 (35%) GT3a. HCV GT1 pre-
dominated among those with and without an IDU his-
tory (found in 11/18 and 18/27 respectively).
Markers of liver injury or fibrosis
Figure 1 indicates the number of women with APRI
and/or FIB-4 available; this group were similar to those
without APRI and/or FIB-4 in terms of HCV co-
infection (30% (231/762) vs 33% (342/1031) respectively,
p = 0.20), IDU history (20% in each group (150/753 and
203/997) p = 0.82) and age (Wilcoxon-Mann-Whitney
rank sum test p = 0.66); however, women with an APRI
score were more likely to have WHO stage 3-4 HIV dis-
ease than those without (20% (149/758) vs 16% (164/
1030), p = 0.04) and HBV co-infection (19% (146/762) vs
16% (161/1031) respectively, p = 0.049).
Table 2 shows markers of liver injury and fibrosis by
co-infection status. Among 899 women with liver en-
zyme data, median AST and ALT levels were 30 U/L
(IQR 19-47) and 24 U/L (IQR 18-39) respectively.
Among the HIV/HCV co-infected women, just over half
had ALT levels above 41 U/L and 84% had a level above
19 U/L; 61% had AST above ULN of 38 U/L (Table 2).
Overall 4.5% (34/762) women had an APRI score >1.5,
indicating significant fibrosis, and 1% (9/761) of women
had a FIB-4 score >3.25, indicating advanced fibrosis.
HCV co-infected women had higher FIB-4 scores overall
than those without HCV infection (Table 2, Wilcoxon-
Mann-Whitney rank-sum test p < 0.01) and were less
likely to have a FIB-4 score <1.45 (Table 2).
Factors associated with significant fibrosis (APRI >1.5)
In univariable analyses, APRI score >1.5 was associated
with HCV seropositivity, IDU history, more advanced
HIV disease, smoking and increasing age (Table 3). In
multivariable analyses adjusting for these factors plus
HBV co-infection and postnatal ART, associations be-
tween significant fibrosis and HCV co-infection, IDU
history and more advanced HIV disease were all attenu-
ated (reflecting their inter-correlation) but remained sta-
tistically significant (Table 3). Smoking and age were no
longer associated with risk of significant fibrosis, how-
ever women on ART were less likely to have an APRI
score >1.5 than untreated women.
Although IDU history and WHO stage remained inde-
pendently associated with APRI score >1.5 after adjust-
ing for HCV co-infection, there was a significant
interaction between IDU history and HCV co-infection
status (p = 0.031). Fitting the final model above, but re-
stricted to HIV/HCV co-infected women (n = 219),
showed that IDU was not associated with significant fi-
brosis (AOR 2.30, 95% CI 0.76-6.95) in this sub-group.
Eighteen women included in the main multivariable
model had a tuberculosis diagnosis. In a sensitivity ana-
lysis excluding these women, the association between
WHO stage 3-4 disease and APRI >1.5 remained largely
unchanged (AOR 3.70 95% CI 1.56-8.78, p = 0.003) as
did the associations between HCV co-infection and
APRI score >1.5 (AOR 2.96, 95% CI 1.17-7.47, p = 0.022)
and IDU and APRI score >1.5 (AOR 3.39, 95% CI 1.32-
8.72, p = 0.011).
Discussion
In this cohort of young childbearing HIV-positive
women, over half of whom had been diagnosed with
HIV in the preceding 18 months, a third were co-
infected with HCV. Half of the HIV/HCV co-infected
group had an ALT measure above 41 U/L compared
Fig. 1 Availability of surrogate biomarkers of liver fibrosis. Footnote: The
APRI /FIB-4 score was available a median of 5.9 months [IQR 3.8-7.3] after
delivery, with 56% (n= 424) having the required blood tests score
reported at postnatal cohort enrolment and 44% (n= 338) at a
follow-up visit
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with one in six of those with HIV mono-infection; the
proportions with significant fibrosis (APRI score >1.5)
were 12% and 2.5% respectively. Overall, 84% of HIV/
HCV co-infected women had an ALT measure above 19
U/L (a level found to have 76% sensitivity in identifying
HCV viraemia among 209 HCV antibody positive blood
donors in Italy [21]). A more detailed characterisation of
HCV RNA in a sub-group of women indicated a likely
spontaneous clearance rate of around 18% (compared
with 23% in a pan-European study of HIV-positive pa-
tients [24]) and a predominance of GT1, although with
one-third having GT3 infection.
Factors associated with increased risk of significant fi-
brosis in adjusted analyses were HCV co-infection, IDU
history, more advanced HIV disease, and no postnatal
ART. Overall, 17% of women were HBV co-infected, in-
creasing to 24% among those HCV-seropositive.
Hepatitis B has been associated with more rapid liver fi-
brosis progression among HIV mono-infected and HIV/
HCV co-infected individuals [25, 26] but its role in liver
fibrosis progression may be complicated by potential in-
teractions of hepatitis B and/or delta virus with HCV to
suppress HCV viremia, or vice versa [27, 28]. HBsAg-
positive women were less likely to have significant fibro-
sis than HBsAg-negative women in adjusted analyses, al-
though this did not reach statistical significance (p =
0.085). Increasing age was not associated with significant
fibrosis in this young cohort, with median age 28 years.
Prevalence of HCV co-infection among HIV-positive
women with an IDU history here was 79%, in line with
previous estimates for Ukraine [29] and more generally
for IDUs in transitional countries [30]. Women with a
history of IDU had increased risk of significant fibrosis
even after adjusting for HCV and HBV co-infection,
Table 2 Markers of liver injury or fibrosis by viral hepatitis co-infection status
HIV
Mono-infection
HIV/HCV
Co-infection
HIV/HBV
Co-infection
HIV/HCV/HBV
Co-infection
Total
n (%) or median [IQR]
ALT
Number with measurement available 514 231 91 63 899
Measure above 19 U/L 269 (52.3) 195 (84.4) 60 (65.9) 52 (82.5) 576 (64.1)
Measure above 41 U/L 64 (12.5) 122 (52.8) 18 (19.8) 11 (17.5) 215 (23.9)
DAIDS grading (ULN taken as 41 U/L)
Grade 1, mild 33 (6.4) 72 (31.2) 9 (9.9) 10 (15.9) 124 (13.8)
Grade 2, moderate 3 (0.6) 21 (9.1) 0 0 24 (2.7)
Grade 3 or 4, severe /potentially life threatening 0 7 (3.0) 0 0 7 (0.8)
AST
Number with measurement available 514 231 91 63 899
Measure above ULN of 38 U/L 127 (24.7) 141 (61.0) 18 (19.8) 18 (28.6) 304 (33.8)
DAIDS grading (ULN 38 U/L)
Grade 1, mild 81 (15.8) 86 (37.2) 12 (13.2) 7 (11.1) 186 (20.7)
Grade 2, moderate 2 (0.4) 25 (10.8) 0 4 (6.4) 31 (3.5)
Grade 3 or 4, severe /potentially life threatening 1 (0.2) 4 (1.7) 0 0 5 (0.6)
APRI score
Number with measure available 445 171 86 60 762
Median APRI [IQR] 0.27 [0.17, 0.42] 0.55 [0.30, 0.92] 0.23 [0.17, 0.34] 0.30 [0.21, 0.43] 0.30 [0.18, 0.52]
< 0.5 (no significant fibrosis) 358 (80.5) 81 (47.4) 74 (86.1) 48 (80.0) 561 (73.6)
0.5-≤ 1.5 (intermediate) 76 (17.1) 69 (40.4) 12 (14.0) 10 (16.7) 167 (21.9)
> 1.5 (significant fibrosis) 11 (2.5) 21 (12.3) 0 2 (3.3) 34 (4.5)
FIB-4
Number with measure available 444 171 86 60 761
Median FIB-4 [IQR] 0.61 [0.39, 0.93] 0.88 [0.59, 1.47] 0.53 [0.36, 0.74] 0.68 [0.50, 0.90] 0.67 [0.42, 1.01]
< 1.45 (no advanced fibrosis) 403 (90.8) 128 (74.9) 85 (98.8) 53 (88.3) 669 (87.9)
1.45-3.25 (intermediate) 37 (8.3) 41 (24.0) 1 (1.2) 4 (6.7) 83 (10.9)
> 3.25 (advanced fibrosis) 4 (0.9) 2 (1.2) 0 3 (5.0) 9 (1.2)
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possibly reflecting hepatotoxic effects of injected sub-
stances. Homemade poppy straw is the drug most
commonly injected in Ukraine and in this cohort
[18], usually taken with a range of other drugs [31]
which may cause liver transaminase elevation. Inject-
ing drug use has itself also been associated with
thrombocytopenia [32], which would result in a
higher APRI score; however, APRI has been validated
in HCV infected individuals among whom IDU is
common.
ART coverage was suboptimal, reflecting the national
situation – only 26% of adults living with HIV in
Ukraine were estimated to be receiving ART in 2013
[33]; here, over a third of women with treatment indica-
tions were not on cART postnatally. Among HIV-
positive people living in Eastern Europe have a higher
incidence of AIDS-related death and lower incidence of
liver-related death than those in the West, reflecting
poorer cART coverage [34]; the proportion of deaths at-
tributable to liver disease in Eastern Europe can be ex-
pected to rise as coverage of cART increases.
We found that women with advanced /severe HIV dis-
ease had a more than three-fold increased risk of signifi-
cant fibrosis, indicating accelerated liver fibrosis
associated with high HIV RNA load and/or the presence
of AIDS-defining diseases with hepatic involvement [35].
Almost three-quarters had stopped antenatal ART by
postnatal cohort enrolment, reflecting the national pre-
vention of mother-to-child transmission (PMTCT) pol-
icy at the time, and untreated women were at
independently increased risk of significant fibrosis. ART
interruptions and/or rebounds in HIV RNA have been
associated with more rapid liver fibrosis progression in
HIV/HCV co-infection patients [36], and short course
ART for PMTCT may be particularly detrimental for this
group’s longer term prognosis. Option B+ (lifelong ART
initiated in all pregnant women with HIV) became na-
tional policy in Ukraine in 2015 and may help to im-
prove postnatal cART coverage, with concomitant
reductions in liver fibrosis progression [37–39].
Among non-IDUs, the 23% HCV co-infection preva-
lence points to potential under-ascertainment of IDU,
Table 3 Factors associated with APRI score >1.5
Proportion with APRI >1.5 (significant fibrosis) Odds ratio
(n = 726)
p value Adjusted odds ratio (n = 726) p value
Hepatitis C antibody status
Negative 2.1% (11/531) 1.00 1.00
Positive 10.0% (23/231) 5.16 (2.50-10.65) <0.001 2.53 (1.03-6.23) 0.044
Hepatitis B surface antigen
Positive 1.4% (2/146) 1.00 1.00
Negative 5.2% (32/616) 3.28 (0.89-12.02) 0.074 3.28 (0.85-12.71) 0.085
History of injecting drug use
No 1.8% (11/603) 1.00 1.00
Yes 15.3% (23/150) 9.15 (4.40-19.01) <0.001 3.51 (1.39-8.89) 0.008
WHO stagea
1–2 2.6% (16/605) 1.00 1.00
3–4 12.4% (18/145) 5.02 (2.52-10.02) <0.001 3.47 (1.51-7.99) 0.003
CD4 counta
> 350 cells/mm3 3.9% (22/563) 1.00
201-350 cells/mm3 5.3% (7/132) 1.46 (0.62-3.42) 0.381
≤ 200 cells/mm3 8.2% (4/49) 2.32 (0.80-6.67) 0.119
Smoker at postnatal cohort enrolment
No 2.7% (11/409) 1.00 1.00
Yes, current smoker 6.8% (23/340) 2.59 (1.26-5.33) 0.010 1.06 (0.46-2.42) 0.896
Age
Per increasing year 1.10 (1.03-1.18) 0.007 1.08 (0.99-1.18) 0.070
Postnatal ARTb
Yes 4.0% (10/253) 1.00 1.00
No 4.8% (24/500) 1.15 (0.55-2.41) 0.715 3.08 (1.23-7.74) 0.017
aClosest to timing of liver function test measures bAt postnatal cohort enrolment
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but also other modes of HCV acquisition including iat-
rogenic acquisition or household/ sexual acquisition
from IDU partners. Heterosexual HCV acquisition risk
may be substantially increased with HIV co-infection
[40] and our study population are at high risk of other
sexually transmitted infections [41] which may act to
synergistically to increase risk of sexual HCV acquisition.
Improved understanding of modes of HCV transmission
in this population is crucial for informing prevention
strategies, including reducing HCV re-infections follow-
ing HCV treatment.
Other published studies of hepatic fibrosis in HIV/
HCV co-infection predominantly include older individ-
uals, the majority males and IDUs, limiting comparisons
with our study. Half of 73 HIV/HCV co-infected women
in the Women’s Interagency HIV Study had significant
fibrosis (defined as liver stiffness ≥7.1 kPa by transient
elastography) [42] while 24% of 800 HIV/HCV co-
infected patients (30% female) enrolled in the Canadian
Coinfection Cohort Study had an APRI score ≥1.5 [43],
similar to 20% in a cohort of 116 HIV/HCV co-infected
patients (36% female) in France, with median age
44 years [44]. Although the HIV/HCV co-infected
women here were 13-15 years younger than individuals
in these studies, 12% already had significant fibrosis. Fu-
ture rates of progression will depend on modifiable risk
factors, for example increasing cART and availability of
HCV treatment. In the Canadian Coinfection Cohort
Study, the incidence rate for progression to an APRI
score ≥1.5 was 14.0/100 person-years among HIV/HCV
co-infected women vs. 8.9/100 person-years among men
[9], thus, the HIV/HCV co-infected women in our co-
hort may represent a high risk group for developing sig-
nificant liver fibrosis based on their gender as well as
current fibrosis rates.
HCV treatment was not publicly funded in Ukraine at
the time of our study. In 2014 a national HCV treatment
programme was launched based on interferon, and in
2015 this was extended to include sofosbuvir, with a
Global Fund-supported pilot scheme also aiming to pro-
vide sofosbuvir treatment to 1500 patients from priority
groups including those with HIV co-infection, from mid-
2015 [45]. The expansion of HCV treatment access
alongside high quality HIV treatment and care is crucial
to prevent avoidable morbidity in HIV/HCV co-infected
people in Ukraine, while in childbearing women the suc-
cessful treatment of HCV could also prevent perinatal
transmissions in future pregnancies.
This study had several limitations. APRI may perform
less well in HIV/HCV co-infection than in HCV mono-
infection, but the >1.5 cut-off used here is highly specific
for significant fibrosis (0.95, 95% CI 0.92-0.97) with
lower sensitivity (0.27 95% CI 0.23-0.31) [46]; the preva-
lence of significant fibrosis we report should therefore
be considered a minimum estimate. Information on duration
of diagnosed HCV was not available (age was used as a
proxy) and we also lacked information on other factors rele-
vant to liver injury, for example alcohol consumption, other
medications and indicators of metabolic syndrome; body
mass index was not interpretable in this cohort of recently
delivered women. Elevated transaminases were based on one
measure only as we lacked repeated measures, and we did
not have information on delta virus which may contribute to
fibrosis progression among those with hepatitis B. As HCV
RNA quantification is not routine in Ukraine, our definition
of HCV co-infection was based on HCV serostatus (in com-
mon with other studies of HIV/HCV co-infection [7]) and
so will have included some women who had spontaneously
cleared the virus; the proportion of HCV viremic women
with APRI score >1.5 may therefore be higher than our esti-
mates for the HIV/HCV co-infected group suggest. Re-
sources to support HCV RNA and GT testing were available
for 56 HIV/HCV co-infected women only as part of this
study. Liver biopsy and/or transient elastography were not
available to validate the non-invasive markers used in this
study, reflecting lack of use / availability in participating HIV
centres. Women with WHO stage 3-4 disease were more
likely to have an APRI score available than those with less
severe HIV disease. Women in this study were engaged with
HIV care and may have a different liver fibrosis risk profile
to the wider HIV-positive population.
Conclusions
There is a high burden of HCV co-infection among
childbearing women living with HIV in Ukraine, particu-
larly among those with an IDU history. Most HIV/HCV
co-infected women had elevated liver enzymes indicating
liver injury, and 12% had significant fibrosis according to
their APRI scores. HCV treatment rates were extremely
low and a high proportion of this population of postnatal
women were not on ART, a situation which is likely to
have changed now that Ukraine has adopted an Option
B+ policy. Our results highlight the importance of ad-
dressing modifiable risk factors and roll-out of HCV
treatment for improving longer term prognosis.
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